US Stock Futures Edge Higher Ahead Of McDonald's Earnings
US stock futures gained in early pre-market trade, ahead of earnings from McDonald's (NYSE: MCD) and Lockheed Martin (NYSE: LMT). The FHFA house price index for February will be released at 9:00 a.m. ET, while existing home sales data for March and the Richmond Fed manufacturing index for April will be released at 10:00 a.m. ET. Futures for the Dow Jones Industrial Average surged 10 points to 16,381.00, while the Standard & Poor's 500 index futures gained 0.60 points to 1,865.00. Futures for the Nasdaq 100 index rose 6.75 points to 3,558.00.
A Peek Into Global Markets
European markets were higher today, with the Spanish Ibex Index rising 0.96%, London's FTSE 100 index gaining 1.01% and STOXX Europe 600 Index surging 1.09%. German DAX 30 index climbed 1.49% and French CAC 40 Index gained 0.83%.
Asian markets ended mostly lower today. Japan's Nikkei Stock Average fell 0.85%, Hong Kong's Hang Seng Index dropped 0.13%, China's Shanghai Composite surged 0.34% and India's BSE Sensex fell 0.03%.
Analysts at Credit Suisse upgraded The NASDAQ OMX Group (NASDAQ: NDAQ) from “neutral” to “outperform.” The target price for NASDAQ OMX Group has been raised from $40 to $42.
NASDAQ OMX Group's shares closed at $35.48 yesterday.
- Eli Lilly and Company (NYSE: LLY) today announced an agreement to acquire Novartis Animal Health (NYSE: NVS) for approximately $5.4 billion in an all-cash transaction that will strengthen and diversify Lilly's own animal health business, Elanco. To read the full news, click here.
- United Technologies (NYSE: UTX) reported better-than-expected first-quarter profit. United Technologies' quarterly net profit dropped 4% to $1.2 billion, or $1.32 per share. To read the full news, click here.
- Novartis (NYSE: NVS) announced today that it has reached a definitive agreement with GlaxoSmithKline plc (NYSE: GSK) to exchange certain assets, building global leadership in key segments and focusing the company's portfolio. To read the full news, click here.
- Salix Pharmaceuticals (NASDAQ: SLXP) and Progenics Pharmaceuticals (NASDAQ: PGNX) announced today that the submission to the European Medicines Agency (EMA) of RELISTOR®(methylnaltrexone bromide) Subcutaneous Injection for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, has been accepted for review. To read the full news, click here.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.